SCHEMBL2855312

SCHEMBL2855312

Nc1ccc(N2CCOCC2)c(C(=O)O)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.60
GAA P10253 9/20 0.59
MAPT P10636 2/20 0.59
KDM4E B2RXH2 7/20 0.56
HSD17B10 Q99714 5/20 0.56
MEN1 O00255 1/20 0.56
THRB P10828 1/20 0.56
ALOX15 P16050 1/20 0.56
GFER P55789 1/20 0.56
YWHAG P61981 1/20 0.56
KMT2A Q03164 1/20 0.56
ALDH1A1 P00352 3/20 0.55
HPGD P15428 1/20 0.55
HTT P42858 1/20 0.55
PKM P14618 1/20 0.53
NPC1 O15118 1/20 0.51
CHRNB2 P17787 1/20 0.51
CHRNA4 P43681 1/20 0.51
RAB9A P51151 1/20 0.50
TOP1 P11387 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18669179 0.88 MAPT (0.55) SMN1; SMN2GAAMAPTKDM4EHSD17B10
SCHEMBL79339 0.88 KDM4E (0.74) SMN1; SMN2GAAMAPTKDM4EHSD17B10
SCHEMBL78016 0.86 MAPT (0.58) SMN1; SMN2GAAMAPTKDM4EHSD17B10
SCHEMBL2336439 0.85 KDM4E (0.76) SMN1; SMN2GAAMAPTKDM4EHSD17B10
SCHEMBL6254176 0.84 HTT (0.77) SMN1; SMN2GAAMAPTKDM4EHSD17B10
SCHEMBL11610621 0.84 HTT (0.77) SMN1; SMN2GAAMAPTKDM4EHSD17B10
SCHEMBL11164417 0.83 ALDH1A1 (0.61) SMN1; SMN2GAAMAPTKDM4EHSD17B10
SCHEMBL17979816 0.82 MAPT (0.54) SMN1; SMN2GAAMAPTKDM4EHSD17B10
SCHEMBL422548 0.82 MAPT (0.56) SMN1; SMN2GAAMAPTKDM4EHSD17B10
SCHEMBL31454335 0.82 MAPT (0.56) SMN1; SMN2GAAMAPTKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570614-B2 Phenyl amino pyrimidine compounds and uses thereof GLAXOSMITH KLINE LLC (US) 2026-03-10 US disclosed
US-20220388967-A1 Phenyl Amino Pyrimidine Compounds and Uses Thereof SIERRA ONCOLOGY, INC. (US) 2022-12-08 US disclosed
US-20210309615-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE LLC 2021-10-07 US disclosed
CN-106573915-B Compounds active against bromodomains 纽韦卢森公司 2020-12-25 CN disclosed
US-10752640-B2 Compounds active towards bromodomains NUEVOLUTION A/S (DK) 2020-08-25 US disclosed
US-10752640-B2 Compounds active towards bromodomains NUEVOLUTION A/S (DK) 2020-08-25 US disclosed
CN-109054648-A Serosity combination for chemically mechanical polishing LTCAM有限公司 2018-12-21 CN disclosed
US-9869027-B2 Cleaning composition and method of manufacturing metal wiring using the same SAMSUNG DISPLAY CO., LTD. (KR) 2018-01-16 US disclosed
US-20170349607-A1 COMPOUNDS ACTIVE TOWARDS BROMODOMAINS NUEVOLUTION A/S (DK) 2017-12-07 US disclosed
US-20170349607-A1 COMPOUNDS ACTIVE TOWARDS BROMODOMAINS NUEVOLUTION A/S (DK) 2017-12-07 US disclosed
US-8486941-B2 Phenyl amino pyrimidine compounds and uses thereof YM BIOSCIENCES AUSTRALIA PTY LTD (AU) 2013-07-16 US disclosed
CN-101861313-A Phenylaminopyrimidine compounds and their use CYTOPIA RES PTY LTD 2010-10-13 CN disclosed
US-20100197671-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE LLC 2010-08-05 US disclosed
EP-2152701-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF Cytopia Research Pty Ltd (AU) 2010-02-17 EP disclosed
WO-2009029998-A1 RETROMETABOLIC COMPOUNDS CYTOPIA RESEARCH PTY LTD (AU) 2009-03-12 WO disclosed
WO-2009029998-A1 RETROMETABOLIC COMPOUNDS CYTOPIA RESEARCH PTY LTD (AU) 2009-03-12 WO disclosed
WO-2008109943-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF CYTOPIA RESEARCH PTY LTD (AU) 2008-09-18 WO disclosed
EP-1833806-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2007-09-19 EP disclosed
WO-2006064189-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-06-22 WO disclosed
US-4066457-A P-PHENYLENEDIAMINE DERIVATIVES GAF CORPORATION (US) 1978-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197671-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF JAK2, JAK1, JAK3 SMN1; SMN2 4595/4885GAA 3092/4885MAPT 3686/4885
US-12570614-B2 Phenyl amino pyrimidine compounds and uses thereof JAK1, JAK2, JAK3 SMN1; SMN2 4092/4885GAA 4694/4885MAPT 4698/4885
US-20170349607-A1 COMPOUNDS ACTIVE TOWARDS BROMODOMAINS BRD4, BRD3, BRDT SMN1; SMN2 2459/4885GAA 1396/4885MAPT 575/4885
US-20210309615-A1 PHENYL AMINO PYRIMIDINE COMPOUNDS AND USES THEREOF JAK2, JAK1, JAK3 SMN1; SMN2 4595/4885GAA 3092/4885MAPT 3686/4885
US-10752640-B2 Compounds active towards bromodomains BRD4, BRD3, BRDT SMN1; SMN2 2459/4885GAA 1396/4885MAPT 575/4885
US-20220388967-A1 Phenyl Amino Pyrimidine Compounds and Uses Thereof JAK2, JAK1, JAK3 SMN1; SMN2 4595/4885GAA 3092/4885MAPT 3686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.